Promedior names Suzanne L. Bruhn president and CEO

Wednesday, May 16, 2012 10:08 AM

Promedior, a Malvern, Penn.-based clinical stage biotech developing novel biologic therapeutics for the treatment of fibrosis, has appointed Suzanne L. Bruhn, Ph.D., as president, CEO and to the board of directors.

Previously, Bruhn served at Shire as senior vice president of strategic planning and program management of the Human Genetic Therapies division, where she played a key leadership role in the development of multiple protein therapeutics for rare, orphan diseases with annual sales today of more than $1 billion. During her tenure at Shire and Transkaryotic Therapies (acquired by Shire in 2005), Bruhn was instrumental in advancing new compounds into clinical development and then continued to manage product strategy, portfolio management, program management and global regulatory affairs for the rare disease portfolio. Before serving with Shire, she served at Cytotherapeutics and played a key role developing the encapsulated cell technology platform for ophthalmic delivery. Bruhn currently serves on the board of directors of Raptor Pharmaceuticals, a public biotechnology company, and Crittenton Women's Union, a local non-profit organization helping low-income women.

Bruhn takes on the role of CEO at a time when Promedior is rapidly advancing its product candidates in human clinical trials for diseases involving fibrosis, including idiopathic pulmonary fibrosis (IPF), myelofibrosis and retinal diseases. She is a seasoned biopharmaceutical leader with experience growing early stage R&D programs through clinical development and product commercialization.

Additionally, as part of the company's evolution, Promedior will move its headquarters and operations to the Boston area to access planned new hires in research and clinical drug development.

"Having recently completed the Series D financing in February and with the company positioned to move into later stage clinical studies within the next year, this was an appropriate time to transition to a new CEO,” said Jim Broderick, M.D., chairman of Promedior and partner at Morgenthaler Ventures. “Sue's strong business leadership and success in commercializing biologic drugs will be a great asset for the company and its growing team."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs